OliPharma Advances Nucleic Acid Therapeutics with Beijing International Nucleic Acid Drug Enabling Technology Platform
Olipharma
CDMO Service Provider
Click the blue words to follow us
Recently, at the monthly work review meeting in Beijing, Municipal Party Secretary Yin Li provided on-site comments on the relevant work of Daxing District. Yin Li pointed out that Daxing District should focus on the overall situation of the city's work, further identify its positioning, leverage its advantages, continuously enhance its development level and modern governance capabilities, and strive to make greater contributions to the development of the entire city."Promote the establishment of the largest nucleic acid drug R&D and production outsourcing platform in the city"Become a major highlight of "consolidating the foundation of industrial development" in Daxing District!
Introduction to Common Technology Platform
June 25, 2024The Common Technology Platform of Beijing International Nucleic Acid Drug Innovation Center, which is constructed and operated by Beijing Oulige under the "Olipharma" brand.Officially open to the public, it is the first specialized carrier in Beijing precisely positioned to support oligonucleotide drug development, aiming to provide comprehensive services for new nucleic acid drug creation, including laboratory development, biological evaluation, analytical testing, pharmaceutical research, registration submission, and more, accelerating the industrialization and internationalization of nucleic acid drugs in China.
This common technology platform includes two major sections: "Biological Research" and "Pharmaceutical Research," enabling the full-process drug development and service system of "Design + Synthesis + Evaluation" on the same platform. The common technology platform is equipped with public laboratories and office areas, adopting an open-access model. It mainly serves various innovative drug formats such as oligonucleotide drugs, oligonucleotide-antibody conjugate drugs, oligonucleotide-peptide conjugate drugs, and gene-editing drugs, striving to become an international benchmark for nucleic acid drug technology platforms.
Ask
Why has the nucleic acid drug common technology service platform received such high attention?
Answer
As a representative of third-generation drugs, small nucleic acid drugs have inherent advantages such as high efficiency, long-lasting effects, and abundant targets, which make them promising in filling the therapeutic gaps left by existing treatments. This emerging field is currently in the early stages of commercialization, with vast room for development. As indications and patient populations continue to expand, the global market size for small nucleic acid drugs is expected to exceed 10 billion US dollars by 2025 and maintain rapid growth over the next two decades. This brings historic development opportunities to the outsourcing industry for the R&D and production of small nucleic acid drugs.
The Common Technology Platform of Beijing International Nucleic Acid Drug Innovation Center focuses on the small nucleic acid drug track. On one hand, it conducts in-depth and continuous development of complex processes such as special modification/delivery, multi-step conjugation, and long-chain nucleic acid synthesis, empowering industry development. On the other hand, the platform provides specialized service carriers and incubation space for innovative nucleic acid drug companies, promoting the application of common technologies and equipment sharing, significantly reducing early R&D investment for innovative drug companies while greatly improving R&D efficiency.The completion of the Beijing International Nucleic Acid Drug Innovation Center's Common Technology Platform is of great significance to the development of the nucleic acid drug industry and even the construction of Beijing as a science and technology innovation center.
Ask
Why Did the Nucleic Acid Drug Common Technology Service Platform Land in China's Pharmaceutical Valley?
Answer
A relevant responsible person from Olipharma stated: "The number of nucleic acid drug R&D projects in Beijing, especially the quantity of original technological achievements from major institutions, has consistently ranked among the top in China. However, Beijing currently lacks a professional contract development and manufacturing organization (CDMO) service platform for nucleic acid drug R&D as well as related incubation platforms."To meet the urgent needs of customers for nucleic acid drug research and development and the transformation of technical achievements, we have decided to build a nucleic acid common technology platform in Beijing to better serve customers in northern China and promote the transformation of advanced technologies."And the reason we chose Daxing Biomedical Industry Base is because of the policy support and thoughtful services here."
The Common Technology Platform of Beijing International Nucleic Acid Drug Innovation Center will continue to uphold the service philosophy of high starting point and high quality, building the platform into a first-class one with strong market competitiveness and excellent service!
About Olipharma
Suzhou Olipharma Technology Co., Ltd. is a professional pharmaceutical nucleic acid CDMO company that provides customers with "one-stop" services including nucleic acid drug discovery, laboratory R&D, process and analytical development, CMC services, API production, and drug registration. The technical team of Olipharma comes from one of the earliest groups in China to engage in the development of nucleic acid drug manufacturing processes and CMC research, possessing extensive experience in project development and product registration. Currently, the company has established four industry-leading core technology platforms: solid-phase nucleic acid synthesis, chemical modification and conjugation, process development and analysis, and CMC pharmaceutical research. It has also engaged in in-depth collaborations with multiple pharmaceutical companies and biotechnology firms both domestically and internationally.
In 2023, the company's 3,000-square-meter GMP-compliant pilot platform officially began offering services, focusing on helping customers address critical challenges such as scaling up small nucleic acid drug production processes and CMC pharmaceutical research. The company will continue to provide compliant, high-quality, reliable, and efficient services to help customers improve R&D efficiency, accelerate product registration and market entry, and jointly support the entire process of small nucleic acid drugs from preclinical to commercial production.
Contact Us
Email: order@olipharma.com
BD Contact: 15336788818 (Same for WeChat)
Official Website: www.olipharma.com
R&D Center: No. 168, Yuanfeng Road, Yushan Town, Kunshan City, Jiangsu Province
Production Base: Building C3, Phase I Factory, No. 999 Yishanhu Road, Guoxiang, Wuzhong District, Suzhou City, Jiangsu Province
Common Technology Platform: 202, 2nd Floor, Building 2, No. 21 Baoshen South Street, Beijing Daxing District Biomedical Industry Base